Australia markets closed

Gamida Cell Ltd. (GMDA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
3.2300+0.2200 (+7.31%)
At close: 04:00PM EDT
3.2500 +0.02 (+0.62%)
Pre-market: 04:32AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close3.0100
Open3.0700
Bid0.0000 x 1800
Ask0.0000 x 900
Day's range3.0350 - 3.3700
52-week range1.4800 - 5.2000
Volume1,166,271
Avg. volume512,267
Market cap193.751M
Beta (5Y monthly)1.71
PE ratio (TTM)N/A
EPS (TTM)-1.5310
Earnings date15 Aug 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est14.40
  • Motley Fool

    Gamida Cell Ltd. (GMDA) Q2 2022 Earnings Call Transcript

    Please be advised that this call is being recorded at Gamida Cell's request. Now, I would like to introduce your host for today's conference, Heather DiVecchia, Gamida Cell's director of investor relations and corporate communications. Welcome to today's call during which we will provide an update on the company and review our financial results for the second quarter of 2022.

  • Business Wire

    Gamida Cell Reports Second Quarter 2022 Financial Results and Provides Company Update

    BOSTON, August 15, 2022--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today provided a business update and reported financial results for the quarter ended June 30, 2022. Net loss for the second quarter of 2022 was $18.6 million, compared to a net loss of $23.6 million in the second quarter of 2021. As of June 30, 2022, Gamida Cell had total cash, cash equivalents and inves

  • Business Wire

    Gamida Cell Announces Dosing of First Patient in Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201

    BOSTON, August 10, 2022--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, announces dosing of the first patient in a company-sponsored Phase 1/2 study evaluating a cryopreserved, readily available formulation of GDA-201 for the treatment of follicular and diffuse large B cell lymphomas (NCT05296525).